Other 🇬🇧, United Kingdom
Poolbeg Pharma develops investigational treatments and is funding an oral GLP-1 proof-of-concept trial alongside its POLB 001 TOPICAL trial. Its activity in this market includes raising capital to support clinical development. This profile follows its financing, partnerships and progress across the programs covered by our monitors.
Market cap not yet added.
Last 12 months
Last 12 months
Investors will provide Poolbeg with £3.5 million in exchange for new shares. Poolbeg says the money will help fund trials of a GLP-1 obesity treatment taken by mouth and a separate cancer-support medicine.
Poolbeg PharmaGrow revenue at each location and build a commercial model that can scale across a clinic group.
Sanor never sells your personal information. By providing this information you agree to Sanor’s Privacy Policy and Terms of Service.
SANOR research follows the principles of ISO 20252:2019 and the ICC/ESOMAR International Code on Market, Opinion and Social Research and Data Analytics, and is conducted in line with our Independence Policy. Our published reports follow our Editorial Standards.
SANOR research is funded through advisory engagements and research licensing. We do not accept vendor sponsorship, paid placement, or advertising.
All publications are provided for general information only. They do not constitute medical, financial, or investment advice and do not account for the circumstances of any specific business or individual.
